Efficacy of circulating plasma DNA as a diagnostic tool for advanced non-small cell lung cancer and its predictive utility for survival and response to chemotherapy

Lung Cancer

Volumn 70, Issue 2, 2010, Pages 211-217

  Kumar, Sachin ^a   Guleria, R ^a   Singh, Vikas ^a   Bharti, Alok C ^b   Mohan, Anant ^a   Das, Bhudev C ^c  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b INSTITUTE OF CYTOLOGY AND PREVENTIVE ONCOLOGY   (India)

^c UNIVERSITY OF DELHI   (India)

Author keywords

Diagnosis; Non small cell lung cancer; Prognosis; Sensitivity; Specificity; Survival

Indexed keywords

DNA; LACTATE DEHYDROGENASE; PLATINUM DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, PHARMACOLOGICAL; CARCINOMA, NON-SMALL-CELL LUNG; CELL COUNT; DNA; FEASIBILITY STUDIES; FEMALE; HUMANS; LEUKOCYTES; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS;

EID: 77956484396     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.01.021     Document Type: Article

References (30)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Can J Clin 2005, 55:74-108.
2. Brambilla C., Fievet F., Jeanmart M., de Fraipont F., Lantuejoul S., Frappat V., et al. Early detection of lung cancer: role of biomarkers. Eur Respir J 2003, 21(Suppl. 39):36s-44s.
3. Henschke C.I., McCauley D.I., Yankelevitz D.F., Naidich D.P., McGuinness G., Miettinen O.S., et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999, 354:99-105.
4. Pastorino U., Bellomi M., Landoni C., De Fiori E., Arnaldi P., Picchio M., et al. Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet 2003, 362:593-597.
5. Lacroix J., Becker H.D., Woerner S.M., Rittgen W., Drings P., von Knebel Doeberitz M. Sensitive detection of rare cancer cells in sputum and peripheral blood samples of patients with lung cancer by preproGRP-specific RT-PCR. Int J Cancer 2001, 92:1-8.
6. Fleischhacker M., Schmidt B. Circulating nucleic acids (CNAs) and cancer-a survey. Biochim Biophys Acta 2007, 1775:181-232.
7. Pathak A.K., Bhutani M., Kumar S., Mohan A., Guleria R. Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin Chem 2006, 52:1833-1842.
8. Detterbeck F.C., Boffa D.J., Tanoue L.T. The new lung cancer staging system. Chest 2009, 136:260-271.
9. Gajalakshmi V., Hung R.J., Mathew A., Varghese C., Brennan P., Boffetta P. Tobacco smoking and chewing, alcohol drinking and lung cancer risk among men in southern India. Int J Cancer 2003, 107:441-447.
10. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
11. Leon S.A., Shapiro B., Sklaroff D.M., Yaros M.J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977, 37:646-650.
12. Sozzi G., Conte D., Mariani L., Lo Vullo S., Roz L., Lombardo C., et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res 2001, 61:4675-4678.
13. Sozzi G., Conte D., Leon M., Ciricione R., Roz L., Ratcliffe C., et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 2003, 21:3902-3908.
14. Beau-Faller M., Gaub M.P., Schneider A., Ducrocq X., Massard G., Gasser B., et al. Plasma DNA microsatellite panel as sensitive and tumor-specific marker in lung cancer patients. Int J Cancer 2003, 105:361-370.
15. Gautschi O., Bigosch C., Huegli B., Jermann M., Marx A., Chassé E., et al. Circulating deoxyribonucleic acid as a prognostic marker in non-small cell lung cancer patients undergoing chemotherapy. J Clin Oncol 2004, 22:4157-4164.
16. Xie G.S., Hou A.R., Li L.Y., Gao Y.N., Cheng S.J. Quantification of plasma DNA as a screening tool for lung cancer. Chin Med J 2004, 117:1485-1488.
17. Herrera L.J., Raja S., Gooding W.E., El-Hefnawy T., Kelly L., Luketich J.D., et al. Quantitative analysis of circulating plasma DNA as a tumor marker in thoracic malignancies. Clin Chem 2005, 51:113-118.
18. Paci M., Maramotti S., Bellesia E., Formisano D., Albertazzi L., Ricchetti T., et al. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. Lung Cancer 2009, 64:92-97.
19. Yoon K.A., Park S., Lee S.H., Kim J.H., Lee J.S. Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls. J Mol Diagn 2009, 11:182-185.
20. van der Drift M.A., Hol B.E., Klaassen C.H., Prinsen C.F., van Aarssen Y.A., Donders R., et al. Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer. Lung Cancer 2009, (July).
21. Szpechcinski A., Struniawska R., Zaleska J., Chabowski M., Orlowski T., Roszkowski K., et al. Evaluation of fluorescence-based methods for total vs. amplifiable DNA quantification in plasma of lung cancer patients. J Physiol Pharmacol 2008, 59(Suppl. 6):675-681.
22. Fournie G.J., Courtin J.P., Laval F. Plasma DNA as a marker of cancerous cell death: investigation in patients suffering from lung cancer and in nude mice bearing human tumour. Cancer Lett 1995, 2:221-227.
23. Lee T.H., Montalvo L., Chrebtow V., Busch M.P. Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma. Transfusion 2001, 41:276-282.
24. Lui Y.Y., Chik K.W., Chiu R.W., Ho C.Y., Lam C.W., Lo Y.M. Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin Chem 2002, 48:421-427.
25. Sozzi G., Roz L., Conte D., Mariani L., Andriani F., Lo Vullo S., et al. Plasma DNA quantification in lung cancer computed tomography screening: five year results of a prospective study. Am J Respir Crit Care Med 2009, 179:69-74.
26. Zitt M., Muller H.M., Rochel M., Schwendinger V., Zitt M., Goebel G., et al. Circulating cell-free DNA in plasma of locally advanced rectal cancer patients undergoing preoperative chemoradiation: a potential diagnostic tool for therapy monitoring. Dis Markers 2008, 25:159-165.
27. Holdenrieder S., Stieber P., VON Pawel J., Raith H., Nagel D., Feldmann K., et al. Early and specific prediction of the therapeutic efficacy in lung cancer by nucleosomal DNA and cytokeratin 19 fragments. Ann N Y Acad Sci 2006, 1075:244-257.
28. Holdenrieder S., von Pawel J., Dankelmann E., Duell T., Faderl B., Markus A., et al. Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer. Lung Cancer 2009, 63:128-135.
29. Gazdar A.F. Personalized medicine and inhibition of EGFR signaling in lung cancer. N Engl J Med 2009, 361:1018-1020.
30. de Marinis F., Grossi F. Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer. Oncologist 2008, 13(S1):14-20.